2 directorsHidden nameVisible after signing in and 1 other
Owners4 names in the annual accounts
consolidatesHidden nameVisible after signing in
Documentsfilings and deeds
10-08-202610 days late
2025financial year
Turnover from €13.3m to €15.3mName after signing inVisible after signing in reappointed as statutory auditor14-10Equity from €5.6m to €8.3mDebts from €5.9m to €4.1mCash from €2.0m to €44,008
Higher net result than 95% of companies in retail trade. The sector median is €59,222, over 2,459 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 17,817 companies had the same profile as INNOMEDIQ has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
Small
10 to 20 years old
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,817 companies, not a prediction for INNOMEDIQ. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Board and ownership
Name after signing inVisible after signing in
Director, Name hiddenVisible after signing in, since 17-12-2025
Hidden nameVisible after signing in
Director, Name after signing inVisible after signing in, since 17-12-2025
Name hiddenVisible after signing in
Auditor, Hidden nameVisible after signing in
Name after signing inVisible after signing in 100%score XXVisible after signing inequity €11.5m (2025) · annual accounts 2023
Hidden nameVisible after signing in 100%equity of Name after signing inVisible after signing in €6.7m (2026) · annual accounts 2021 of Name hiddenVisible after signing in
Since the merger of 23-12-2022, these shares have been held by Hidden nameVisible after signing in.
Name after signing inVisible after signing in consolidatesscore XXVisible after signing inequity €22.2m (2025) · annual accounts 2025
Merger: INNOMEDIQ takes over CF-SYSTEMName hiddenVisible after signing in (director) and Hidden nameVisible after signing in (director) resign · Name after signing inVisible after signing in and Name hiddenVisible after signing in act as permanent representatives · “De vennootschap heeft tot voorwerp, zowel in België als in het buitenland: -De groothandel, detailhandel…” (deed in Dutch) · General meeting of 30-07-2026 · Gazette deed
Merger proposal: INNOMEDIQ takes over CF-SYSTEMHidden nameVisible after signing in and Name after signing inVisible after signing in act as permanent representatives · “Groot- en detailhandel in medische, orthopedische en paramedische artikelen (NACE 47.74); Verhuur en lease van…” (deed in Dutch) · Gazette deed
2 directors appointed, 3 resignationsName hiddenVisible after signing in, Hidden nameVisible after signing in and Name after signing inVisible after signing in resign · Name hiddenVisible after signing in, Hidden nameVisible after signing in, Name after signing inVisible after signing in, Name hiddenVisible after signing in and Hidden nameVisible after signing in act as permanent representatives · Name after signing inVisible after signing in and Name hiddenVisible after signing in appointed · General meeting of 17-12-2025 · Gazette deed
Hidden nameVisible after signing in reappointed as statutory auditorName after signing inVisible after signing in acts as permanent representative · General meeting of 13-06-2025 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
Grey: the largest companies of the sector (retail trade (NACE 47)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as INNOMEDIQ: retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741). They are comparable in size and age: total assets between €4.9m and €12m, founded between 1987 and 2008.
According to the KBO register, the main activity is retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741).
What is the legal form of INNOMEDIQ?
INNOMEDIQ is a public limited company (NV).
When was INNOMEDIQ founded?
INNOMEDIQ was founded on 18-09-2008.
Is INNOMEDIQ still active?
Yes, INNOMEDIQ is an active enterprise in the KBO register.
How many employees does INNOMEDIQ have?
INNOMEDIQ had an average of 25.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does INNOMEDIQ fall under?
In its 2025 annual accounts, INNOMEDIQ states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of INNOMEDIQ?
The turnover of INNOMEDIQ was €15.3m in financial year 2025, according to the filed annual accounts.
Is INNOMEDIQ profitable?
In financial year 2025, INNOMEDIQ made a profit of €2.7m.
Where can I find the annual accounts of INNOMEDIQ?
INNOMEDIQ filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of INNOMEDIQ due?
INNOMEDIQ must file the annual accounts for financial year 2026 by 31-07-2027.Timeline